New trials, publications, preprints and grants on this target, month by month.
Trial
CAR-T Immunotherapy Targeting CD19- ALL
1 Jul 2027· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Universal CAR-T Cells Targeting AML
30 Jun 2027· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
Universal CAR-T Cells Targeting Multiple Myeloma
30 Jun 2027· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
1 Jun 2027· PHASE1 · WITHDRAWN· CTGOV
Trial
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
31 Dec 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
31 Dec 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Phase 2 Trial of 89Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma.
1 Nov 2026· Radiology· PUBMED
Trial
A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments
22 Oct 2026· PHASE4 · NOT_YET_RECRUITING· CTGOV
Publication
Anti-CD38 monoclonal antibodies in kidney disease: mechanistic rationale and emerging clinical evidence.
15 Oct 2026· Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association· PUBMED
Publication
CD38-targeted therapies in kidney disease: evidence maturity, disease-stage dependence, and biomarker-guided retreatment.
14 Oct 2026· Frontiers in medicine· PUBMED
Trial
FT839 in Autoimmune Diseases
1 Oct 2026· PHASE1_PHASE2 · RECRUITING· CTGOV
Trial
Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study"
1 Oct 2026· NA · NOT_YET_RECRUITING· CTGOV
Publication
Synthesis, Evaluation, and Effect of Anti-CD38 Single-chain Immunotoxin on HL-60 acute myeloid Leukemia cell Line.
29 Sept 2026· Current research in translational medicine· PUBMED
Publication
Biparatopic targeting of CD38 using CD38-specific trimeric antibody recruiters improves cytotoxicity against multiple myeloma.
24 Sept 2026· Frontiers in immunology· PUBMED
Publication
Histone H3K18 Lactylation Drives Immunosuppression by Upregulating CD38 in Myeloid-Derived Suppressor Cells in Lung Cancer.
18 Sept 2026· Cancer immunology research· PUBMED
Publication
Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
14 Sept 2026· Leukemia· PUBMED
Publication
Implementation of soluble CD38 in blood crossmatching for patients on anti-CD38 therapy: A single-center experience.
11 Sept 2026· Transfusion· PUBMED
Trial
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
10 Sept 2026· PHASE2 · RECRUITING· CTGOV
Publication
Multimodal analysis of CD38 in T-cell Acute Lymphoblastic Leukemia Identifies Combinatorial Therapeutic Strategies.
2 Sept 2026· Blood· PUBMED
Trial
Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.
1 Sept 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Study of CD38 and CD56 in Chronic Myeloid Leukemia
1 Sept 2026· NA · NOT_YET_RECRUITING· CTGOV
Publication
Anti-CD38 monoclonal antibodies in multiple myeloma and beyond: immunotherapeutic mechanisms, evidence maturity, and clinical positioning.
1 Sept 2026· Frontiers in immunology· PUBMED
Publication
Persistent CD8+ T-cell activation (HLA-DR/CD38) as an immunological marker in antiretroviral-treated human immunodeficiency virus-1 patients: A cross-sectional study.
27 Aug 2026· The Journal of international medical research· PUBMED
Publication
Targeting CD38 in relapsed /refractory T-cell acute lymphoblastic leukemia/lymphoma: A systematic review of daratumumab-based therapy.
25 Aug 2026· Therapeutic advances in hematology· PUBMED
Publication
mRNA-dendritic cell antigen vaccine potentiates CD38 CAR-T Cell therapy for relapsed/refractory acute myeloid leukemia.
24 Aug 2026· Theranostics· PUBMED
Publication
Targeting CD38 Across Autoimmune and Plasma Cell-Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic Landscape.
18 Aug 2026· BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy· PUBMED
Publication
CD38+ T-Cell Count Is an Immunologic Phenotype Associated With Blood Pressure.
17 Aug 2026· Hypertension (Dallas, Tex. : 1979)· PUBMED
Trial
A Open-Label Phase in Participants With Multiple Myeloma
15 Aug 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
CD38 Inhibition Enhances FXR Signaling in Male Rats With Diabetic Steatohepatitis Through SIRT1-Dependent Suppression of NLRP3.
15 Aug 2026· FASEB journal : official publication of the Federation of American Societies for Experimental Biology· PUBMED
Publication
Gut Microbiome Composition Is Associated With Response to CD38 Antibody (Daratumumab) Treatment Among Relapsed Multiple Myeloma Patients.
10 Aug 2026· Clinical lymphoma, myeloma & leukemia· PUBMED